A Phase 1 study of RAD1901, an oral selective estrogen receptor degrader, in ER positive, HER2 negative, advanced breast cancer patients.

Elisabeth G. E. de Vries, Clasina Marieke Venema, Andor W. J. M. Glaudemans, Lorraine Fitzpatrick, Dinesh Purandare, Gary Hattersley, Fiona Garner

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Number of pages2
JournalJournal of Clinical Oncology
Volume34
Issue number15
DOIs
Publication statusPublished - 20-May-2016
EventAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, United States
Duration: 2-Jun-20176-Jun-2017

Cite this